Millennium Management LLC boosted its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 23,182.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 497,551 shares of the specialty pharmaceutical company’s stock after purchasing an additional 495,414 shares during the period. Millennium Management LLC owned approximately 0.95% of Supernus Pharmaceuticals worth $13,672,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Patriot Financial Group Insurance Agency LLC purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at about $33,000. Private Capital Group LLC increased its position in shares of Supernus Pharmaceuticals by 108.0% during the second quarter. Private Capital Group LLC now owns 1,379 shares of the specialty pharmaceutical company’s stock worth $83,000 after acquiring an additional 716 shares during the period. Point72 Hong Kong Ltd increased its position in shares of Supernus Pharmaceuticals by 324.1% during the second quarter. Point72 Hong Kong Ltd now owns 1,692 shares of the specialty pharmaceutical company’s stock worth $56,000 after acquiring an additional 1,293 shares during the period. First Mercantile Trust Co. raised its stake in shares of Supernus Pharmaceuticals by 31.5% during the third quarter. First Mercantile Trust Co. now owns 2,173 shares of the specialty pharmaceutical company’s stock valued at $60,000 after acquiring an additional 520 shares in the last quarter. Finally, Redhawk Wealth Advisors Inc. bought a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $202,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:SUPN opened at $22.91 on Friday. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of 11.18, a PEG ratio of 0.86 and a beta of 1.54. Supernus Pharmaceuticals Inc has a 52 week low of $19.35 and a 52 week high of $43.05. The company has a quick ratio of 2.68, a current ratio of 2.85 and a debt-to-equity ratio of 0.66. The firm has a 50 day moving average of $24.29 and a 200 day moving average of $28.48.
Several research analysts recently issued reports on the company. ValuEngine raised Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. Stifel Nicolaus cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the stock from $55.00 to $23.00 in a report on Thursday, November 7th. Zacks Investment Research raised Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Berenberg Bank downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $46.50.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
See Also: Blockchain
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.